|
|
|
27.03.26 - 04:30
|
Research: Citi Raises TP of INNOVENT BIO to HKD115, Rating 'Buy' (AAStocks)
|
|
|
Citi published a research report indicating that INNOVENT BIO (01801.HK) saw its revenue rise by 38% year-on-year to RMB13 billion last year, with a net profit of RMB834 million, turning from a loss to a profit year-on-year. The management reiterated the guidance for product sales to reach RMB20 billion by 2027. The management n......
|
|
|
|
|
|
|
|
|
26.03.26 - 11:03
|
Innovent Announces 2025 Annual Results and Business Updates (PR Newswire)
|
|
|
From China Leadership to Global Premier: Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that......
|
|
|
|
|
|
|
|
|
23.03.26 - 01:03
|
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study (PR Newswire)
|
|
|
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,......
|
|
|
|
|
|
|
|
|
|
|
|
|
10.02.26 - 04:00
|
Hong Kong stocks extend bounce-back from tech turbulence as risk sentiment returns (SCMP)
|
|
|
Hong Kong stocks gained, extending a rebound from a sell-off in technology companies, as traders returned to the risk-on mode on bets that the tumult has run its course.
The Hang Seng Index rose 0.9 per cent to 27,258.08 as of 10.37am local time. The Hang Seng Tech Index climbed 1.1 per cent. On the mainland, the CSI 300 Index and the Shanghai Composite Index both added 0.1 per cent.
CSPC Pharmaceutical Group rallied 5.5 per cent to HK$10.32, and biotech firm Innovent Biologics gained 5.3 per......
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
